Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05741359 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Jan 20, 2024 to Nov 20, 2026
    • Study completion date: Mar 15, 2024 to Jan 15, 2027
    v3
  2. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 3
    • Start date changed from estimate of Mar 30, 2023 to Apr 25, 2023
    • Study arms: 3 to 1
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a multi-center, single-arm, open-label clinical study, and the sample size is set to 12-18 subjects.
Trial Details
NCT Number NCT05741359
Lead Sponsor Bioray Laboratories
Collaborators: Chinese Academy of Medical Sciences, Zhejiang University, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Conditions
(from sponsor)		 Non-hodgkin Lymphoma,B Cell
Enrollment 18 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov